on Exyte
Exyte Successfully Integrates Pharmaplan to Boost Biopharma Engineering Capabilities
Exyte has completed the integration of Pharmaplan, unifying biopharma engineering capabilities within its European operations. The acquisition, announced in September 2024, aims to strengthen Exyte's position in the biotechnology and pharmaceutical sectors across Europe. This integrated setup has resulted in increased client demand and record order-intake levels in 2025.
The integration marks a significant milestone for Exyte, expanding its Life Sciences services to over 40 locations in 12 countries. Exyte now offers end-to-end EPC/EPCM services, from feasibility studies to compliant handover, in major life sciences markets.
With a global network of experts and digital engineering capabilities, Exyte maintains its competitive advantage. It combines a history of expertise in GMP environments with modern digital tools to deliver complex projects efficiently and reliably. The company's methods emphasize speed, regulatory compliance, and sustainability, catering to evolving industry trends.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Exyte news